case
sever
acut
respiratori
syndrom
sar
report
hong
kong
earli
march
earli
june
almost
death
new
case
report
sinc
june
current
epidem
appear
hong
kong
nevertheless
fear
diseas
resurg
season
basi
remain
effort
must
made
understand
pathogen
mechan
identifi
improv
treatment
novel
coronaviru
sarscoronaviru
sarscov
identifi
caus
agent
sar
number
rapidli
publish
studi
describ
epidemiolog
clinic
present
manag
lung
patholog
syndrom
patholog
chang
sar
suggest
proinflammatori
cytokin
releas
stimul
macrophag
alveoli
promin
role
pathogenesi
sar
result
cytokin
dysregul
current
studi
begun
valid
sensit
specif
diagnost
test
sar
necess
clinic
diagnosi
empir
antibiot
therapi
target
bacteria
commonli
respons
communityacquir
pneumonia
import
diagnost
therapeut
strategi
nonsar
pneumonia
gener
respond
therapi
patient
respond
presenc
featur
consist
sar
combin
corticosteroid
ribavirin
therapi
given
howev
consider
sceptic
use
drug
sar
current
consist
effect
antisarscov
therapi
recoveri
sar
like
requir
earli
adequ
correctli
regul
inflammatori
respons
depend
proinflammatori
cytokin
interleukin
il
tumour
necrosi
factoralpha
antiinflammatori
cytokin
deriv
mainli
mononuclear
phagocyt
celldepend
cytokin
interferongamma
presum
import
orchestr
specif
immun
respons
clear
viru
therefor
undertook
analysi
cytokin
product
patient
sar
order
improv
understand
diseas
pathogenesi
improv
patient
manag
studi
approv
joint
institut
review
board
queen
mari
hospit
univers
hong
kong
thirteen
patient
satisfi
world
health
organ
center
diseas
control
cdc
criteria
probabl
sar
studi
tabl
epidemiolog
link
sar
patient
one
demonstr
sarscov
nasopharyng
aspir
nasal
throat
swab
faec
urin
sputum
revers
transcriptasepolymeras
chain
reaction
rtpcr
document
antisarscov
igg
antibodi
serum
eight
male
five
femal
age
mean
year
patient
treat
cours
intraven
cefepim
g
three
time
per
day
oral
clarithromycin
mg
twice
per
day
also
receiv
ribavirin
mgkg
three
time
per
day
intraven
day
follow
mg
three
time
per
day
oral
total
day
corticosteroid
intraven
hydrocortison
methylprednisolon
mean
day
start
mean
day
admiss
follow
oral
prednisolon
mean
day
patient
unev
recoveri
daili
dose
steroid
shown
fig
one
sar
patient
die
fulmin
pneumonia
day
admiss
anoth
die
respiratori
failur
due
diffus
alveolar
damag
day
admiss
one
kept
intens
care
day
admiss
patient
discharg
hospit
day
underli
chronic
diseas
five
patient
tabl
sar
patient
compar
data
healthi
chines
subject
similar
age
sex
distribut
sar
patient
ie
male
age
year
mean
femal
age
year
mean
number
cytokinesecret
peripher
blood
mononuclear
cell
pbm
determin
use
enzymelink
immunospot
elispot
assay
detail
adapt
method
specif
reproduc
report
briefli
pbm
separ
lymphoprep
nycom
oslo
norway
within
h
blood
collect
ad
multiscreen
plate
millipor
bedford
usa
coat
previous
overnight
cytokin
captur
antibodi
pharmingen
san
diego
ca
usa
ph
block
fetal
calf
serum
fc
cultur
medium
least
h
duplic
cultur
cellswel
rpmi
fc
without
stimul
cell
activ
phytohaemagglutinin
pha
final
concentr
concanavalin
con
monocyt
activ
staphylococcu
aureu
cowan
sac
vv
incub
h
cell
wash
phosphatebuff
salin
contain
tween
pbst
plate
incub
sequenti
biotinyl
detect
anticytokin
antibodi
pharmingen
pbst
min
phosphatas
sigma
st
loui
mo
usa
vv
pbst
min
tetrazolium
calbiochem
la
jolla
ca
usa
min
room
temperatur
plate
wash
extens
pbst
incub
salin
remov
phosphat
prior
addit
phosphatas
substrat
colour
develop
stop
viru
inactiv
immers
chlorox
follow
rins
tap
allow
plate
dri
h
blue
spot
correspond
cytokinesecret
cell
count
microscopi
result
express
pbm
cell
lymphocyt
subset
b
cell
cell
helper
cell
cytotox
cell
andor
natur
killer
nk
cell
enumer
use
commerci
monoclon
antibodi
beckman
coulter
miami
fl
usa
dual
colour
flow
cytometri
epic
xlmcl
coulter
white
cell
differenti
count
perform
standard
method
cytokin
profil
evalu
sar
patient
day
indic
tabl
onset
symptom
assum
approxim
day
admiss
four
patient
evalu
start
treatment
total
evalu
patient
perform
patient
hospit
receiv
corticosteroid
patient
retest
twice
recoveri
day
admiss
receiv
low
dose
steroid
treatment
cell
seen
unstimul
cultur
sar
patient
normal
control
agreement
previou
studi
number
phainduc
secret
cell
lower
limit
normal
almost
sar
patient
earli
cours
diseas
approxim
half
patient
reduc
fig
due
entir
suppress
high
dose
steroid
four
subject
test
start
treatment
also
defici
number
previous
depress
elispot
becam
normal
patient
week
first
symptom
similar
profil
obtain
result
adjust
accord
absolut
cell
count
patient
result
avail
fig
similar
result
also
obtain
use
con
stimul
result
shown
unstimul
secret
cell
within
normal
rang
two
sar
patient
normal
unstimul
fig
contrast
sacinduc
greatli
increas
sacinduc
greatli
reduc
nearli
hospit
sar
patient
low
sacinduc
seen
three
four
patient
test
start
steroid
therapi
number
sacinduc
cell
decreas
steroid
therapi
level
normal
still
seen
two
patient
week
first
symptom
greater
concern
sacstimul
cell
return
normal
week
unstimul
phastimul
sacstimul
cell
increas
hospit
sar
patient
chang
greatli
treatment
steroid
fig
secret
cell
especi
induc
pha
sac
increas
major
patient
higher
normal
level
still
seen
mani
patient
week
fig
three
sar
patient
consid
poor
outcom
two
die
hospit
one
kept
intens
care
day
admiss
patient
high
level
secret
cell
first
day
follow
hospit
fig
haematolog
data
given
fig
white
cell
count
rais
sar
patient
present
due
neutrophilia
lymphocyt
percentag
low
monocyt
percentag
often
white
blood
cell
wbc
count
neutrophil
percentag
decreas
normal
week
lymphocyt
monocyt
percentag
increas
case
higher
normal
level
percentag
b
cell
normal
rais
earli
stage
diseas
fell
treatment
cell
percentag
especi
cell
reduc
half
patient
studi
percentag
cell
nk
cell
remain
rel
normal
studi
period
sar
epidem
began
urgent
need
gather
inform
rapidli
possibl
pathogen
mechan
develop
treatment
could
minim
damag
lung
believ
measur
cytokin
product
pbm
vitro
could
assist
achiev
goal
howev
face
difficulti
identifi
sarscovinfect
patient
studi
earli
stage
diseas
without
fulli
valid
rapid
diagnost
test
consequ
number
patient
nonsar
commun
acquir
pneumonia
test
inadvert
cytokin
product
exclud
later
recov
antibiot
therapi
bacteri
rather
viral
natur
infect
patient
constitut
valid
control
group
could
nonsar
viral
pneumonia
cohort
recruit
rariti
patient
hong
kong
therefor
possibl
evalu
result
sar
patient
term
establish
laboratori
normal
rang
although
detail
includ
report
patient
suspect
initi
sar
respond
dose
antibiot
describ
materi
method
sar
patient
show
normal
level
cell
reduc
half
subject
normal
phainduc
rais
sacinduc
normal
phainduc
low
sacinduc
increas
defici
respons
cell
activ
much
greater
sar
nonsar
pneumonia
due
possibl
corticosteroid
treatment
former
wherea
respons
monocyt
activ
sac
similar
magnitud
despit
expect
suppress
effect
steroid
anoth
studi
communityacquir
pneumonia
also
show
rais
plasma
use
enzymelink
immunosorb
assay
elisa
concentr
serum
found
even
higher
acut
respiratori
distress
syndrom
sever
pneumonia
clarithromycin
shown
decreas
product
proinflammatori
cytokin
lung
mice
chronic
pseudomona
aeruginosa
infect
lung
inflamm
induc
live
kill
mycoplasma
pneumonia
influenc
antibiot
cytokin
profil
sar
nonsar
pneumonia
patient
rule
last
year
obtain
inform
result
use
elispot
techniqu
number
clinic
situat
cytokin
elispot
assay
exquisit
sensit
hand
detect
subtl
chang
due
minor
ill
tissu
injuri
b
jone
unpublish
stress
standard
panel
cytokin
type
cytokin
type
cytokin
proinflammatori
cytokin
antiinflammatori
cytokin
provid
inform
overal
balanc
within
immun
system
result
must
howev
interpret
conjunct
knowledg
lymphocyt
subset
monocyt
content
isol
pbm
represent
individu
subset
greatli
influenc
cytokin
profil
must
also
appreci
cytokin
produc
vitro
pbm
may
fulli
repres
event
organ
bodi
lung
measur
cytokin
solubl
cytokin
receptor
cytokin
inhibitor
serum
inform
increas
level
transform
growth
found
serum
sar
patient
latter
studi
also
found
increas
serum
contrast
find
use
elispot
import
confirm
result
describ
use
techniqu
flow
cytometri
intracellular
cytokin
rtpcr
cytokin
messeng
ribonucl
acid
sar
patient
lymphopaen
treatment
steroid
treatment
would
appear
sarscov
preferenti
induc
deplet
lymphocyt
circul
b
cell
fell
normal
mani
patient
treatment
still
week
rais
concern
develop
effect
antibodi
respons
sarscov
might
compromis
howev
cell
cell
nk
cell
greatli
disturb
clearli
defici
nk
cellderiv
cytokin
due
simpli
deplet
subset
peripher
blood
inde
express
result
cellderiv
cytokin
cell
alter
profil
fig
studi
suggest
import
cytokin
establish
cellmedi
humor
immun
includ
respons
requir
clear
sarscov
defici
sar
entir
due
treatment
immunosuppress
corticosteroid
patient
recov
normal
product
cytokin
week
start
symptom
defici
product
respons
mitogen
activ
sac
still
present
time
product
follow
direct
stimul
monocyt
appar
disrupt
greater
extent
sarscov
andor
steroid
treatment
induc
phaactiv
cell
via
interact
possibl
higher
level
inhibitori
sacstimul
cultur
high
number
antiinflammatori
proinflammatori
cell
present
earli
diseas
remain
elev
although
fall
treatment
corticosteroid
mani
patient
still
higher
normal
andor
cell
sever
week
releas
hospit
corticosteroid
inhibit
cytokin
chemokin
adhes
molecul
product
antagon
action
proinflammatori
cytokin
interf
jakstat
intracellular
signal
pathway
howev
even
prolong
high
dose
use
studi
fail
reduc
rapidli
product
inflammatori
cytokin
better
antiinflammatori
therapi
urgent
need
antisarscov
therapi
attempt
ribavirin
also
appear
limit
valu
reduc
proinflammatori
cytokin
secondarili
neutral
infect
viru
ribavirin
report
directli
decreas
product
proinflammatori
cytokin
switch
type
cytokin
respons
type
strong
evid
occur
patient
two
sar
patient
die
one
slow
recoveri
number
cell
first
day
symptom
among
highest
record
could
perhap
indic
especi
high
viru
burden
especi
vigor
inflammatori
respons
either
could
engend
exagger
patholog
respons
lung
studi
compar
larger
number
patient
good
bad
outcom
need
determin
whether
measur
proinflammatori
cytokin
immedi
appear
symptom
would
use
prognost
indic
